Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of December 2023, with a filing date of December 6, 2023. The report details a corporate governance change regarding the company's American Depositary Shares (ADS) program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the resignation of The Bank of New York Mellon (BONY) as the company's depositary and the appointment of JPMorgan Chase Bank, N.A. as the successor depositary. This change was effective upon appointment on December 5, 2023, with JPMorgan expected to commence services on or about December 18, 2023.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the administrative transition of the depositary agreement. A Second Amended and Restated Deposit Agreement will take effect upon JPMorgan's commencement of service. Holders of American depositary receipts will become parties to this new agreement. The filing does not provide operational guidance, risk factors, or contingencies beyond this administrative update.
Investor Verification Checklist
- Confirm the effective date of JPMorgan Chase Bank, N.A. as the new depositary (expected December 18, 2023).
- Review the Second Amended and Restated Deposit Agreement filed as Exhibit (a) to Form F-6 (File No. 333-275909) for updated terms and conditions.
- Verify that existing American depositary receipts have been deemed amended and restated under the new agreement.